{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009643","form_type":"8-K","ticker":null,"cik":"0001722964","company_name":"Y-mAbs Therapeutics, Inc.","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.272815+00:00","generated_at":"2026-06-01T00:05:06.547099+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Y-mAbs names Peter Pfreundschuh CFO; outgoing CFO Bo Kruse to assist transition to July 31","bullets":["Peter Pfreundschuh appointed CFO and Treasurer effective June 28, 2024; succeeds Bo Kruse who will assist transition through July 31, 2024.","Base salary $500,000; eligible for annual cash bonus up to 45% of base; receives initial option to purchase 170,000 shares and 46,000 RSUs.","Pfreundschuh previously CFO at Voyager, Frequency, UroGen, Sucampo; earlier roles at J&J, AstraZeneca, Ernst & Young.","Company highlights commercial traction with DANYELZA and advancement of SADA-PRIT radioimmunotherapy platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009643","json":"https://secwatch.observer/filing/0001558370-24-009643.json","markdown":"https://secwatch.observer/filing/0001558370-24-009643.md","text":"https://secwatch.observer/filing/0001558370-24-009643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/ymab-20240627x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:05:06.547099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c246cf1bb","claim":"Bo Kruse departed as Chief Financial Officer and Treasurer at Y-mAbs Therapeutics, Inc..","evidence_excerpt":"succeeded Bo Kruse, who is expected to remain available to the Company for a period of time following the conclusion of his employment on July 31, 2024, during which time Mr. Kruse will assist in the transition of his responsibilities and duties.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departing"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"5f79a77233","claim":"Peter Pfreundschuh was appointed as Chief Financial Officer and Treasurer at Y-mAbs Therapeutics, Inc..","evidence_excerpt":"On June 27, 2024, the Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) appointed Peter Pfreundschuh to serve as the Company’s Chief Financial Officer and Treasurer, effective June 28, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}